Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

mikesterz7 May. 14 at 2:22 AM

$OMER Omeros is now awaiting a European Medicines Agency decision on the Yartemlea marketing authorization application.

2 · Reply

hmb May. 14 at 1:59 AM

$OMER truly a deal below $14. Bring it down.

0 · Reply

stockpimpbot5000 May. 14 at 1:20 AM

$OMER What is crazy, is that... it was a quarter that finished... almost... two months ago.........

2 · Reply

Merlintrader May. 14 at 12:59 AM

$OMER UPDATED with earnings Omeros Q1 2026: YARTEMLEA Starts With $9.9M Net Sales, CMS J-Code Arrives, and Launch Execution Becomes the Main Story https://www.merlintrader.com/omeros-corporation-stock-hub/

0 · Reply

Smellystocks May. 14 at 12:54 AM

$OMER that 2029 note gonna burn your asses. Bears gonna feast on this rotting corpse tomorrow. Gonna be glorious.

7 · Reply

Fire7878 May. 14 at 12:35 AM

$OMER so Greg just sold his option exersize back to the company?

3 · Reply

StocktwitsNews May. 14 at 12:19 AM

OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations $OMER $VTI $IWM https://stocktwits.com/news/equity/markets/omer-stock-gains-ground-as-commercial-rollout-of-yartemlea-exceeds-expectations/cZX1IZZReKt

0 · Reply

EVZ May. 14 at 12:17 AM

$OMER Great Q1 earnings call, but pathetic AH price movement. Let’s see if this is a sell the news scenario.

1 · Reply

BanaT May. 13 at 11:55 PM

$OMER Can someone explain how the derivative notes work and how going up in share price causes a loss?

2 · Reply

vu_jade May. 13 at 11:50 PM

$OMER Decent report .. Will go higher

0 · Reply

Omeros Earnings Call Transcript: Q1 2026

2026-05-13T20:27:08.000Z - 6 hours ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)

May 13, 2026, 4:02 PM EDT - 7 hours ago

Omeros Corporation Reports First Quarter 2026 Financial Results

2026-05-13T19:54:34.000Z - 7 hours ago

Omeros options imply 10.8% move in share price post-earnings

May 11, 2026, 4:02 PM EDT - 2 days ago

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-05-04T12:45:05.000Z - 9 days ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

KYTX

2026-04-16T14:14:18.000Z - 27 days ago

Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA

Apr 16, 2026, 8:45 AM EDT - 27 days ago

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Mar 31, 2026, 4:30 PM EDT - 6 weeks ago

Omeros Earnings Call Transcript: Q4 2025

2026-03-31T20:05:48.000Z - 6 weeks ago

Omeros reports Q4 EPS $1.22, consensus 36c

Mar 31, 2026, 4:02 PM EDT - 6 weeks ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 26, 2026, 8:45 AM EDT - 6 weeks ago

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 21, 2026, 3:23 AM EDT - 7 weeks ago

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

2026-02-17T14:15:38.000Z - 3 months ago

Omeros announces completion of nonhuman primates OncotoX-AML study

Feb 17, 2026, 8:45 AM EST - 3 months ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

2026-01-27T14:20:24.000Z - 3 months ago

Omeros announces first commercial sales of Yartemlea

Jan 27, 2026, 9:00 AM EST - 3 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®

2026-01-08T11:11:35.000Z - 4 months ago

Omeros price target raised to $40 from $20 at H.C. Wainwright

Jan 7, 2026, 6:50 PM EST - 4 months ago

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 4:30 PM EST - 4 months ago

Omeros Transcript: FDA Announcement

2025-12-30T15:45:11.000Z - 4 months ago

Omeros call volume above normal and directionally bullish

2025-12-29T16:45:08.000Z - 4 months ago

Omeros call volume above normal and directionally bullish

Dec 26, 2025, 6:36 PM EST - 4 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

2025-12-24T15:55:07.000Z - 5 months ago

D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating

2025-12-24T15:30:10.000Z - 5 months ago

H.C. Wainwright says Yartemlea approval ‘significant validation’ of Omeros value

2025-12-24T15:15:15.000Z - 5 months ago

Omeros trading resumes

2025-12-24T15:10:19.000Z - 5 months ago

Omeros trading halted, volatility trading pause

2025-12-24T15:10:08.000Z - 5 months ago

Omeros up 100% at $17.55 upon resumption of trading

2025-12-24T14:40:42.000Z - 5 months ago

Omeros to resume trading at 9:50 am ET

2025-12-24T14:05:07.000Z - 5 months ago

Omeros announces FDA approved YARTEMLE for treatment of TA-TMA

Dec 24, 2025, 9:05 AM EST - 5 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 5 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

2025-12-24T11:45:14.000Z - 5 months ago

Omeros trading halted, news pending

Dec 1, 2025, 8:30 AM EST - 5 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 13, 2025, 4:30 PM EST - 6 months ago

Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:11 PM EST - 6 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 6 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 16, 2025, 8:30 AM EDT - 7 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 11:54 AM EDT - 7 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 7 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 7 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 7 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 9 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:02 PM EDT - 9 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 9 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 10 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 11 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 1 year ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 1 year ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Nov 21, 2024, 9:15 AM EST - 1 year ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:02 PM EST - 1 year ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:11 PM EST - 1 year ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Oct 24, 2024, 8:45 AM EDT - 1 year ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Jun 3, 2024, 9:00 AM EDT - 2 years ago

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

May 15, 2024, 4:30 PM EDT - 2 years ago

Omeros Earnings Call Transcript: Q1 2024

May 15, 2024, 4:02 PM EDT - 2 years ago

Omeros Corporation Reports First Quarter 2024 Financial Results

mikesterz7 May. 14 at 2:22 AM

$OMER Omeros is now awaiting a European Medicines Agency decision on the Yartemlea marketing authorization application.

2 · Reply

hmb May. 14 at 1:59 AM

$OMER truly a deal below $14. Bring it down.

0 · Reply

stockpimpbot5000 May. 14 at 1:20 AM

$OMER What is crazy, is that... it was a quarter that finished... almost... two months ago.........

2 · Reply

Merlintrader May. 14 at 12:59 AM

0 · Reply

Smellystocks May. 14 at 12:54 AM

$OMER that 2029 note gonna burn your asses. Bears gonna feast on this rotting corpse tomorrow. Gonna be glorious.

7 · Reply

Fire7878 May. 14 at 12:35 AM

$OMER so Greg just sold his option exersize back to the company?

3 · Reply

StocktwitsNews May. 14 at 12:19 AM

0 · Reply

EVZ May. 14 at 12:17 AM

$OMER Great Q1 earnings call, but pathetic AH price movement. Let’s see if this is a sell the news scenario.

1 · Reply

BanaT May. 13 at 11:55 PM

$OMER Can someone explain how the derivative notes work and how going up in share price causes a loss?

2 · Reply

vu_jade May. 13 at 11:50 PM

$OMER Decent report .. Will go higher

0 · Reply

opmankc May. 13 at 11:45 PM

$OMER I am actually surprise we choose to buyback some shares 👀 does it mean nvo payment is coming so we have no cash pressure?

1 · Reply

StatsGuru May. 13 at 11:42 PM

$OMER Great sign - During the three months ended March 31, 2026, we repurchased and retired approximately 0.4 million shares of common stock pursuant to our share repurchase program, at an average cost of $11.70 per share, for an aggregate purchase price of $4.2 million.

0 · Reply

MikeLogan May. 13 at 11:38 PM

$OMER Well it is good to know that in the event of this happening, Greg believes the shares are undervalued enough that he will likely be back on Deck buying them up from impatient retailers with the 100 million dollar share buyback..

3 · Reply

Stat_Czar May. 13 at 11:24 PM

$OMER never really runs after hours on earnings. Always seems to stretch a little the next day or next few days after. EMA should move the dial and should be incoming in very short order. Pretty soon, this stock will not be as cheap as it is now.

0 · Reply

Fire7878 May. 13 at 11:03 PM

$OMER seems like everything is on track or ahead of schedule, nice surpise on the buy back. Potential competition seems to be moving goal post on thier study results which isnt a good sign for them on how those results were looking (wonder who tipped the coverage to ensure that was highlighted). Accelerating payer approvals and getting interest in earlier intervention because the results have been so positive seems like a spirl towards sucess. Look forward to scooping some shares from people to inpatient to wait for a bump from EMA or milestone achievement.

0 · Reply

Squagster May. 13 at 10:53 PM

$OMER Welp, it gained back what it lost today anyway. I see the huge potential but honestly, I can’t justify it if it does not move next week it’s kinda like dead money and i need my money working or paying a dividend. Good luxk to u guys and i hope it moons soon for u!

1 · Reply

izacmann May. 13 at 10:52 PM

$OMER one day we will pop post earnings. One. Day.

0 · Reply

jmmoore4 May. 13 at 10:42 PM

$OMER Great call with sucky AH price movement.

1 · Reply

OmeRUN May. 13 at 10:37 PM

$OMER OMS721 revenue was reported today. Warms my long time investor heart. Hope all of you are well. Cheers!

2 · Reply

MayorofMNKD May. 13 at 9:52 PM

$OMER …excellent call! Once the impatient day traders sell us their stock we will proceed the climb to $20 as we get closer to EMA approval! ….and that starts tomorrow friends! $100 stock

1 · Reply

TarponTime May. 13 at 9:52 PM

$OMER you really can’t ask anymore out of Dr greg than what we just received!!! That makes 3 tremendous conference calls in a row!!! Expanding the label to include Alzheimer’s, Parkinson’s, ARDS, and Renal failure… Those who have been around long enough to remember Omidria and the issues regarding J code reimbursement… when you have a drug that demands $36,000 per dose ,,,, JCode is essential!! We Own TA-TMA !!! SUCK ON THAT SERGE !!!

3 · Reply

EarningsInsider May. 13 at 9:46 PM

https://www.marketbeat.com/earnings/reports/2026-5-13-omeros-co-stock/ $OMER Omeros Earnings Transcript

0 · Reply

Market Cap	1.07B
Revenue (ttm)	0.00
Net Income (ttm)	-3.35M
EPS (ttm)	N/A
PE Ratio	8.11
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.72

Volume	2,370,700
Avg Vol	1,101,738
Day's Range	N/A - N/A
Shares Out	72.17M
Stochastic %K	39%
Beta	2.66
Analysts	Strong Sell
Price Target	$43.67